Spectral Medical (TSE:EDT) has released an update.
Spectral Medical has made significant strides in its Tigris trial, enrolling 135 out of 150 patients, despite challenges like Hurricane Helene affecting supply chains. The company has secured $11 million in funding, ensuring it can complete the trial by early 2025 and work towards potential FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Adds an Ad-Supported Tier in Europe
- How Ford (NYSE:F) Looks to Solve Its Hydrogen Engine Problem
- The Intel (NASDAQ:INTC) “Coffee Debacle” Is Now Solved
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
